Article
Medicine, General & Internal
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.
Article
Oncology
Fatih Gurler, Aysegul Ilhan, Deniz Can Guven, Okan Turhan, Bediz Kurt Inci, Osman Sutcuoglu, Fatih Yildiz, Zafer Arik, Berna Oksuzoglu, Suayib Yalcin, Nuriye Ozdemir, Ozan Yazici, Ahmet Ozet
Summary: This study retrospectively compared the efficacy and safety of FOLFOX and FLOT regimens as first-line treatment for metastatic gastric cancer. The findings suggest that FLOT regimen may be a preferred option with improved progression-free survival and objective response rate compared to FOLFOX regimen.
Article
Oncology
Melanie Dos Santos, Justine Lequesne, Alexandra Leconte, Stephane Corbinais, Aurelie Parzy, Jean-Marc Guilloit, Sharmini Varatharajah, Pierre-Emmanuel Brachet, Marine Dorbeau, Dominique Vaur, Louis-Bastien Weiswald, Laurent Poulain, Corentin Le Gallic, Marie Castera-Tellier, Marie-Pierre Galais, Benedicte Clarisse
Summary: This study aims to evaluate the efficacy and safety of Spartalizumab in combination with the FLOT regimen as perioperative treatment for resectable gastric or GEJ adenocarcinoma. The study plans to enroll up to 67 patients using a Simon's two-stage design, with 23 patients in the first stage. The main endpoint is the proportion of patients with pathological complete regression (pCR) in the primary tumor after preoperative treatment.
Review
Oncology
Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao
Summary: The incidence of gastric/gastroesophageal junction (G/GEJ) cancer remains high globally, especially in China. Patients with early-stage G/GEJ adenocarcinoma have a better prognosis after surgery, while those with advanced metastatic G/GEJ adenocarcinoma have a less optimistic long-term survival outlook. The identification of various biomarkers, particularly microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutational burden (TMB), and Epstein-Barr virus (EBV), has significantly improved the clinical efficacy of treatments for G/GEJ adenocarcinoma by identifying targeted populations. HER2-targeted therapy has shown excellent clinical outcomes for patients with advanced HER2-positive G/GEJ adenocarcinoma, although some patients develop resistance.
BIOMARKER RESEARCH
(2022)
Review
Oncology
Daniel V. T. Catenacci, Minori Rosales, Hyun Cheol Chung, Harry H. Yoon, Lin Shen, Markus Moehler, Yoon-Koo Kang
Summary: This study describes the design and rationale of a clinical trial evaluating the use of margetuximab plus retifanlimab or margetuximab plus tebotelimab in unresectable metastatic/locally advanced gastric/gastroesophageal junction adenocarcinoma as first-line therapy. Primary endpoints include objective response rate, overall survival, and safety/tolerability.
Article
Oncology
Cagatay Arslan, Fatos Dilan Atilla
Summary: The modified DCF (mDCF) regimen and capecitabine maintenance have shown high efficacy and longer time to progression (TTP) in the first-line treatment of metastatic gastric cancer (MGC).
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Takuro Saito, Yukinori Kurokawa, Tsuyoshi Takahashi, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki
Summary: This retrospective study examined the efficacy and safety of neoadjuvant docetaxel, oxaliplatin, and S-1 combination chemotherapy in patients with adenocarcinoma of the esophagogastric junction (AEG). The results showed that neoadjuvant DOS therapy in AEG produced high rates of pathological complete response and acceptable toxicities, suggesting it may be a promising treatment strategy.
Article
Oncology
Sun Young Rha, Do-Youn Oh, Patricio Yanez, Yuxian Bai, Min-Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai-Keen Shiu, Manuel Gonzalez Fernandez, Jin Li, Maeve A. Lowery, Timucin Cil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A. Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan S. Wyrwicz
Summary: This study compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy for locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. The results showed that participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity.
Article
Oncology
Shannon Stockton, Paul Catalano, Steven J. Cohen, Barbara A. Burtness, Edith P. Mitchell, Efrat Dotan, Sam J. Lubner, Pankaj Kumar, Mary F. Mulcahy, George A. Fisher, Theodore L. Crandall, Al Benson
Summary: This randomized phase II trial compared the efficacy of paclitaxel (arm A) and paclitaxel plus cixutumumab (arm B) as second-line therapy for patients with metastatic esophageal or gastroesophageal junction cancers. The results showed that the addition of cixutumumab to paclitaxel did not significantly improve clinical outcomes, including progression-free survival and overall survival, compared to standard of care. Therefore, cixutumumab did not show enhanced efficacy when combined with paclitaxel in the treatment of metastatic esophageal/GEJ cancer.
Article
Oncology
Amelie Deleporte, Marc Van den Eynde, Frederic Forget, Stephane Holbrechts, Thierry Delaunoit, Ghislain Houbiers, Hassan R. Kalantari, Stephanie Laurent, Erik Vanderstraeten, Marc De Man, Philippe Vergauwe, Marylene Clausse, Jacques Van der Auwera, Lionel D'Hondt, Pascal Pierre, Bjorn Ghillemijn, Angelique Covas, Marianne Paesmans, Lieveke Ameye, Ahmad Awada, Francesco Sclafani, Alain Hendlisz
Summary: This trial found that fractionated weekly and fortnightly DCF regimens have a low risk of early FN and a better hematological toxicity profile when treating metastatic gastric adenocarcinoma patients. Both regimens offer greater convenience compared to historical DCF, without the need for systematic use of prophylactic G-CSF.
Review
Oncology
Julien Taieb, Jaafar Bennouna, Frederique Penault-Llorca, Debora Basile, Emmanuelle Samalin, Aziz Zaanan
Summary: This review describes the current standards of management for early and late stage gastric adenocarcinoma, and discusses the molecular markers required for optimal patient management. The review also provides insights into future perspectives of this disease.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Giulia Grizzi, Fausto Petrelli, Maria Di Bartolomeo, Matteo Viti, Mariana Texeira Moraes, Andrea Luciani, Rodolfo Passalacqua, Michele Ghidini, Gianluca Tomasello, Gian Luca Baiocchi, Andrea Celotti
Summary: This network meta-analysis provides further evidence for the optimization of treatment strategies for gastric and gastroesophageal junction (GEJ) adenocarcinoma. It confirms that incorporating perioperative triplet-based chemotherapy improves overall survival (OS) and disease-free survival (DFS) compared to surgery alone and other preoperative strategies.
Article
Oncology
I. Nakayama, D. Takahari, K. Chin, T. Wakatsuki, M. Takamatsu, N. Yamamoto, M. Ogura, A. Ooki, K. Fukuda, H. Osumi, S. Fukuoka, E. Shinozaki, K. Yamaguchi
Summary: A study was conducted to assess the characteristics and treatment outcomes of patients with HER2-low G/GEJ adenocarcinoma. It was found that these patients exhibited distinct features and worse prognosis compared to HER2-negative patients, highlighting the need for novel therapeutic strategies targeting HER2-low G/GEJ adenocarcinoma.
Article
Surgery
Gianluca Businello, Valentina Angerilli, Sara Lonardi, Francesca Bergamo, Michele Valmasoni, Fabio Farinati, Edoardo Savarino, Gaya Spolverato, Matteo Fassan
Summary: The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has improved targeted and effective treatments, introducing biomarkers into clinical practice. The evaluation mainly relies on limited biopsy material, making pathologists essential in patient selection for precision medicine approaches.
UPDATES IN SURGERY
(2023)
Article
Oncology
Andrea Ghezzi, Jessica Rossi, Francesco Cavallieri, Manuela Napoli, Rosario Pascarella, Romana Rizzi, Marco Russo, Gaetano Salomone, Antonio Romano, Corrado Iaccarino, Elisabetta Froio, Silvia Serra, Salvatore Cozzi, Lucia Giaccherini, Franco Valzania, Anna Pisanello
Summary: A rare case of pituitary metastasis from gastric cardia adenocarcinoma is reported in this article. The patient presented with symptoms of diabetes insipidus and visual deterioration. Surgical removal of the pituitary mass revealed adenocarcinoma of uncertain origin. This case highlights the importance of considering pituitary metastasis as a potential cause for diabetes insipidus and visual impairment, especially without evidence of other metastatic sites.
FRONTIERS IN ONCOLOGY
(2023)